Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
The big problem Mani has with the assertion that BP won’t enter into a deal until we’ve done a P2 is the fact Astra Zeneca already did just that in 2015.
At that point all we had was a tiny proof of concept trial. Now we have data from global trials.
BP to all kinds of caveat deals tiered to results at different stages.
This probably doesn’t fit with Mani’s desperate attempts to so negative positions.
There are two obvious points on communication although one is more fanciful than the other.
Either they know and are deliberately withholding information from shareholders. I’m guessing you can figure out which one that is, or they are just not ready yet.
Whether or not you’re happy with them not being ready depends on how realist your views are about the timeframes that drug development takes.
I’m happy to wait and our case remains a strong one. BP and government bodies don’t care how impatient you are for progress on trials or JV’s. They move when they’re ready.
We had a healthy financial balance at the last interims and the trials haven’t started yet so our financial situation should still be good. We just need partners for the next phase. I’m confident those partners exist
Who would spend their time on a board making the same points repeatedly about a company or drug they believe doesn’t have a future.
Trolls are irrational.
But science-minded people are not, which is why Sakura7 is not what they pretend to be.
What is Repetition Bias? Repeated information feels more true.
Thanks to Repetition Bias, the more times a message is repeated, and the greater the number of sources repeating the message, the more believable it becomes.
Oh dear
The daily threads of the ultimate tangential summariser, supported by the conductor of the orchestra of gloom and doubt, who now proclaims the cold unit trolls are being cruelly treated.
What a sad place this board has become.
News is coming one way or another, but beware this board because it’s full of sharks and not all of them have obvious fins.
Https://journals.asm.org/doi/10.1128/jvi.01204-23
However, a trend in lower hospitalizations was observed in patients treated with SNG001 [86% relative risk reduction (P = 0.07)] (128). These three studies highlight the need for additional research into the effect of the route of administration/site of drug delivery not just for IFN-I but for all COVID-19 candidate therapeutics. In particular, given that SARS-CoV-2 is a respiratory virus, efforts should focus on evaluating nasal and oral inhalation routes to promote drug distribution to the respiratory mucosa.
An RNS is based on news not the time elapsed since the last one
When they have something to tell us we will get the RNS we all want.
Until then patience and a reality check on how long it takes to develop a drug trial, particularly one that’s so important to the company’s existence.
The reality is trials and the science that backs them up takes a great deal of time to bring to fruition.
People got a false sense of urgency during COVID that things would happen within months. You could equally say that one of our biggest failures in Sprinter was rushing the trial design.
I remain patient knowing we will either get an update before H2 is ends or at the AGM. Our largest investor appears equally calm about the finances and our progress.
Summary:
Using a novel protein-structure-based B cell epitope discovery method with a wide range of possible applications, we have identified a simple to measure host-pathogen antibody signature associated with severe COVID-19 and longCOVID and suggest the viral Membrane protein contains an epitope that acts as a T independent antigen during infection triggering extrafollicular B cell activation.
Structural epitope profiling identifies antibodies associated with critical COVID-19 and long COVID
https://www.medrxiv.org/content/10.1101/2022.07.11.22277368v4
Where does it mention Synairgen?
Here
“Precision medicine for pandemics: stratification of COVID-19”
And Here
Together with Scientists from Medicine and Biological Sciences and University spin out company, Synairgen, TopMD will lead molecular phenotyping in a €14m EU-funded international consortium for COVID-19 advanced diagnostics.
TopMD co-founders, James Schofield, Lecturer in Systems Biomedicine and Paul Skipp, Associate Professor in Proteomics will work with a number of other University of Southampton researchers and academics in leading the DRAGON project.
And Here
“A significant proportion of medical research seeks to better understand
complex, heterogeneous patient and population groups, and to divide them
into subclasses defined by markers.
Stratified, precision, P4 or personalised medicine has the ultimate goal to
ensure that the right patient receives the right therapy at the right time“
https://synairgen.ams3.digitaloceanspaces.com/230629-Synairgen-AGM-2023_FINAL.pdf
Synairgen have always been in the foreground of this kind of collaborative process.
It seems one of the many interests are co founder has is
Precision medicine for pandemics!
I wonder who else in BP and world government organisations might have similar interests?